… -stage untreated primary tumours and late-stage treated metastatic tumours using a harmonized
pan-cancer analysis (or reanalysis) of two unpaired primary 4 and metastatic 5 cohorts …

… of metastatic competence and active molecular pathways. A deeper understanding of
molecular signatures of metastatic … targets and drug regimens to cure metastatic dissemination. …

… differentially drive progression, metastasis, and drug … primary tumor cells exhibit a metastatic
genetic signature. However, specific mutations can still promote invasion and metastasis in …

… In a clinical trial encompassing 20 cohorts of patients with advanced solid tumors, …
signature as an accurate and independent predictive biomarker has been validated in a pan-cancer …

… Furthermore, we will review TMB variability across solid tumors with implications for cutoff
selection, its association with benefit from ICIs, and strategies to optimize TMB as a predictive …

… Original full-text research articles reporting PD-L1, PD-1, PD-L2, TIL, TMB, or MSI status
in both primary solid tumours and paired metastases were included. Both prospective and …

… De novo MET amplifications are found across a wide variety of solid tumours. These
amplifications are typically identified in <1–5% of non-small-cell lung cancers (NSCLCs) 30,60,61,62…

… CAFs constitute one of the most abundant stromal components in solid tumors. CAFs are
distinguished from different cell subtypes based on the presence of several stromal markers, …

… The purpose of this study was to assess potential associations of molecular signatures
with CAT, including tumor-specific mutations and the presence of clonal hematopoiesis. We …

… Activation of the MET gene, which is known to mediate invasive growth, commonly
occurs as a late event in solid tumours and is associated with increased metastatic potential. …